

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

212038Orig1s000

Trade Name: Adhansia XR, 25mg/35mg/45mg/55mg/70mg/85mg

Generic or Proper Name: Methylphenidate hydrochloride extended-release capsules

Sponsor: Purdue Pharma L.P.

Approval Date: February 27, 2019

Indication: For the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

CENTER FOR DRUG EVALUATION AND RESEARCH

212038Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	X
Statistical Review(s)	X
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

212038Orig1s000

APPROVAL LETTER



NDA 212038

NDA APPROVAL

Purdue Pharma L.P.
Attention: Nadine Bouchard, B. Sc.
Associate Director, Global Regulatory Affairs
1 Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901

Dear Ms. Bouchard:

Please refer to your New Drug Application (NDA) dated and received April 27, 2018, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Adhansia XR (methylphenidate hydrochloride) extended-release capsules 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg.

This new drug application provides for the use of Adhansia XR (methylphenidate hydrochloride) extended-release capsules for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5)*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 212038.**” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for ages 0 to less than 4 years because necessary studies are impossible or highly impracticable. This is because the diagnostic criteria and assessment measures for determining efficacy for the treatment of ADHD in children less than 4 years old are not well defined and studies in this age group are a challenge regarding patient safety and study validity. Pharmaceutical treatment in this age group is uncommon and non-medication interventions are preferred treatment for behavioral disorders such as ADHD in very young children (e.g., less than 4 years of age).

We are deferring submission of your pediatric studies for ages 4 to less than 6 years for this application because this product is ready for approval for use in pediatric patients 6 to 17 years old, and the studies in patients 4 to less than 6 years have not been completed.

Your deferred pediatric studies required by section 505B(a) of the FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. These required studies are listed below.

- | | |
|--------|--|
| 3570-1 | Conduct an open-label, randomized, multiple-dose, safety, tolerability, and pharmacokinetic study of Adhansia XR (methylphenidate hydrochloride) extended-release capsules in male and female children (4 to less than 6 years |
|--------|--|

of age) with ADHD. The Sponsor proposes to extrapolate efficacy using the PK data in children 4-5 years of age.

Final Protocol Submission: August 2019
Study/Trial Completion: August 2021
Final Report Submission: February 2022

- 3570-2 Conduct a one-year, open-label extension study to obtain additional information on safety and tolerability of Adhansia XR (methylphenidate hydrochloride) extended-release capsules in children age 4 to 12 years of age diagnosed with ADHD.

Final Protocol Submission: August 2019
Study/Trial Completion: March 2024
Final Report Submission: September 2024

Submit the protocols to your IND 118297, with a cross-reference letter to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

This product is appropriately labeled for use in ages 6 to 17 years for this indication. Therefore, no additional pediatric studies are needed in this pediatric group.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact CAPT Bill Bender, Senior Regulatory Project Manager, at (301) 796-2145 or via email at william.bender@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tiffany R. Farchione, M.D.
Director (Acting)
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Prescribing Information
Medication Guide
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TIFFANY R FARCHIONE
02/27/2019 06:42:46 PM